185 related articles for article (PubMed ID: 35321433)
1. Successful Treatment of a Patient With Multiple-Line Relapsed Extensive-Stage Small-Cell Lung Cancer Receiving Penpulimab Combined With Anlotinib: A Case Report.
Zhang Z; Li Y; Dong Y; Li J; Zhang B; Zhang C; Cui X
Front Oncol; 2022; 12():846597. PubMed ID: 35321433
[TBL] [Abstract][Full Text] [Related]
2. Penpulimab and anlotinib in an elderly patient with recurrent cervical cancer: a case report and literature review.
Niu G; Wang H; Ren Y; Xing X; Zhao L; Liu N; Wen X; Zhai Y
Immunotherapy; 2023 Aug; 15(12):905-912. PubMed ID: 37340883
[TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy of ICI plus anlotinib vs. anlotinib alone as third-line treatment in extensive-stage small cell lung cancer: a retrospective study.
Chen Q; Li Y; Zhang W; Wang C; Yang S; Guo Q
J Cancer Res Clin Oncol; 2022 Feb; 148(2):401-408. PubMed ID: 34797416
[TBL] [Abstract][Full Text] [Related]
4. The occurrence of asthma in an extensive-stage small-cell lung cancer patient after combination therapy with atezolizumab and anlotinib: a case report.
Deng W; Chen J; Deng XY
Front Immunol; 2024; 15():1333850. PubMed ID: 38487532
[TBL] [Abstract][Full Text] [Related]
5. Long-term survival in extensive-stage small-cell lung cancer treated with different immune checkpoint inhibitors in multiple-line therapies: A case report and literature review.
Zhang X; Zheng J; Niu Y; Xue C; Yu Y; Tan K; Cui H
Front Immunol; 2022; 13():1059331. PubMed ID: 36532013
[TBL] [Abstract][Full Text] [Related]
6. Corrigendum: Successful treatment of a patient with multiple-line relapsed extensive-stage small-cell lung cancer receiving penpulimab combined with anlotinib: A case report.
Zhang Z; Li Y; Dong Y; Li J; Zhang B; Zhang C; Cui X
Front Oncol; 2022; 12():980842. PubMed ID: 36033531
[TBL] [Abstract][Full Text] [Related]
7. Carrelizumab combined with anlotinib in the treatment of extensive-stage small cell lung cancer: A case report.
Liu L; Zhang X; Zhou L; Yang T; Qiao Y; Jiang X
Medicine (Baltimore); 2021 Sep; 100(35):e27138. PubMed ID: 34477165
[TBL] [Abstract][Full Text] [Related]
8. Clinical Activity and Safety of Penpulimab (Anti-PD-1) With Anlotinib as First-Line Therapy for Unresectable Hepatocellular Carcinoma: An Open-Label, Multicenter, Phase Ib/II Trial (AK105-203).
Han C; Ye S; Hu C; Shen L; Qin Q; Bai Y; Yang S; Bai C; Zang A; Jiao S; Bai L
Front Oncol; 2021; 11():684867. PubMed ID: 34327136
[TBL] [Abstract][Full Text] [Related]
9. Toripalimab combined with anlotinib for recurrent extensive‑stage small‑cell lung cancer: A case report.
Wu Y; Chen Y; Yang Z
Exp Ther Med; 2023 Jul; 26(1):313. PubMed ID: 37273750
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness and Safety of Anlotinib Monotherapy for Patients with Extensive-stage Small-Cell Lung Cancer Who Progressed to Chemotherapy: A Real-world Exploratory Study.
Li Y; Sun Z; Sun W; Wang H; Zu J
Clin Med Insights Oncol; 2022; 16():11795549211067184. PubMed ID: 35095286
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of PD-1/PD-L1 inhibitor plus chemotherapy versus chemotherapy alone as first-line treatment for extensive-stage small cell lung cancer: A systematic review and meta-analysis.
Zhang S; Li S; Cheng Y
Thorac Cancer; 2020 Dec; 11(12):3536-3546. PubMed ID: 33058504
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of fluzoparib combined with anlotinib in extensive stage small cell lung cancer after first-line platinum-based chemotherapy: a multi-center, single-arm prospective phase II clinical study (STAMP study).
Li D; Huang Z; Zhong J; Lin L; Zhang G; Zhuang W; Liu Z
BMC Cancer; 2023 Aug; 23(1):753. PubMed ID: 37580661
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of anlotinib as maintenance therapy after induction chemotherapy in extensive-stage small-cell lung cancer.
Wang N; Zhao L; Zhang D; Kong F
Anticancer Drugs; 2023 Apr; 34(4):558-562. PubMed ID: 36728981
[TBL] [Abstract][Full Text] [Related]
14. Intracranial complete response to toripalimab and anlotinib in a patient with recurrent brain metastases of small cell lung cancer after failure of second-line maintenance therapy: a case report.
Huang F; Tang J; Lou J; Wang Q; Ma K; Qiao R; Si J; Kang Y; Chen H; Mei J; Wang H; Liu Y; Miao L
Transl Cancer Res; 2022 Sep; 11(9):3337-3342. PubMed ID: 36237231
[TBL] [Abstract][Full Text] [Related]
15. Successful Treatment of an Elderly Patient With Combined Small Cell Lung Cancer Receiving Anlotinib: A Case Report.
Gan Y; Liu P; Luo T
Front Oncol; 2021; 11():775201. PubMed ID: 34858856
[TBL] [Abstract][Full Text] [Related]
16. Anlotinib combined with PD-1 blockade for the treatment of lung cancer: a real-world retrospective study in China.
Zhang X; Zeng L; Li Y; Xu Q; Yang H; Lizaso A; Mao X; Jin R; Zeng Y; Li Q; Wang J; Li Y; Zhang Y; Yang N
Cancer Immunol Immunother; 2021 Sep; 70(9):2517-2528. PubMed ID: 33566148
[TBL] [Abstract][Full Text] [Related]
17. The efficacy and safety of anlotinib combined with platinum-etoposide chemotherapy as first-line treatment for extensive-stage small cell lung cancer: A Chinese multicenter real-world study.
Zheng HR; Jiang AM; Gao H; Liu N; Zheng XQ; Fu X; Ruan ZP; Tian T; Liang X; Yao Y
Front Oncol; 2022; 12():894835. PubMed ID: 36203439
[TBL] [Abstract][Full Text] [Related]
18. The Efficacy and Safety of Anlotinib in Extensive-Stage Small Cell Lung Cancer: A Multicenter Real-World Study.
Zheng HR; Jiang AM; Gao H; Liu N; Zheng XQ; Fu X; Zhang R; Ruan ZP; Tian T; Liang X; Yao Y
Cancer Manag Res; 2022; 14():2273-2287. PubMed ID: 35942069
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and Safety of Anlotinib for Elderly Patients with Previously Treated Extensive-Stage SCLC and the Prognostic Significance of Common Adverse Reactions.
Song PF; Xu N; Li Q
Cancer Manag Res; 2020; 12():11133-11143. PubMed ID: 33173346
[TBL] [Abstract][Full Text] [Related]
20. Anlotinib as third- or further-line therapy for short-term relapsed small-cell lung cancer: subgroup analysis of a randomized phase 2 study (ALTER1202).
Shi J; Cheng Y; Wang Q; Li K; Wu L; Han B; Chen G; He J; Wang J; Qin H; Li X
Front Med; 2022 Oct; 16(5):766-772. PubMed ID: 35844026
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
